Alexandre Altié

Mr. Alexandre Altié

CNRS

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
KMKilian Mazaleyrat
Kilian Mazaleyrat
CBCherif Badja
Cherif Badja
NBNatacha Broucqsault
Natacha Broucqsault
RCRaphael Chevalier
Raphael Chevalier
CLCamille Laberthonnière
Camille Laberthonnière
FMFrederique Magdinier
Frederique Magdinier
Induced pluripotent stem cells (iPSCs) obtained by reprogramming primary somatic cells have revolutionized the fields of cell biology and disease modeling. However, the number protocols for generating mature muscle fibers with sarcolemmal organization using iPSCs remain limited, and partly mimic the complexity of mature skeletal muscle. Methods: We used a novel combination of small molecules added in a precise sequence for the simultaneous codifferentiation of human iPSCs into skeletal muscle cells and motor neurons. Results: We show that the presence of both cell types reduces the production time for millimeter-long multinucleated muscle fibers with sarcolemmal organization. Muscle fiber contractions are visible in 19–21 days, and can be maintained over long period thanks to the production of innervated multinucleated mature skeletal muscle fibers with autonomous cell regeneration of PAX7-positive cells and extracellular matrix synthesis. The sequential addition of specific molecules recapitulates key steps of human peripheral neurogenesis and myogenesis. Furthermore, this organoid-like culture can be used for functional evaluation and drug screening. Conclusion: Our protocol, which is applicable to hiPSCs from healthy individuals, was validated in Duchenne Muscular Dystrophy, Myotonic Dystrophy, Facio-Scapulo-Humeral Dystrophy and type 2A Limb-Girdle Muscular Dystrophy, opening new paths for the exploration of muscle differentiation, disease modeling and drug discovery.

24 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
PHPierre HAEN
Pierre HAEN
LCLydie Crescence
Lydie Crescence
DMDiane Mege
Diane Mege
AAAlexandre Altié
Alexandre Altié
Christophe DuboisChristophe Dubois
Christophe Dubois
LPLaurence Panicot-Dubois
Laurence Panicot-Dubois
Venous thrombo-embolism (VTE) disease is the second most common cause of mortality in cancer patients, and evaluation and prevention of thrombosis risk is essential. VTE-associated risk varies according to the type of tumor disease. Oral cancer is the most frequent type of head and neck cancer, and it represents approximately 2.1% of all cancers worldwide. Most tumors are squamous cell carcinomas and are mainly due to tobacco and alcohol abuse. VTE risk associated with oral squamous cell carcinoma (OSCC) is low. However, many studies have shown that OSCC has the following biological features of cancers associated with a high thrombosis risk: modified thrombosis and fibrinolysis mechanisms; strong expression of procoagulant proteins; secretion of procoagulant microparticles; and production of procoagulant cytokines. Using an original mouse model of tongue squamous cell carcinoma, our study aimed to clarify this paradoxical situation. First, we showed that OSCC tumors have a pro-aggregatory phenotype and a high local thrombosis risk. Second, we found that tongue tumor mice do not have an elevated systemic thrombosis risk (the risk of an “at distance” thrombosis event such as lower extremity deep venous thrombosis or pulmonary embolism) and even show a reduction in risk. Third, we demonstrated that tongue tumor mice show a reduction in platelet reactivity, which explains the low systemic thrombosis risk. Finally, we found that tongue tumor mice present granule pool deficiency, thereby explaining the reduction in platelet reactivity and systemic thrombosis risk.

7 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMones Saleh
Mones Saleh
BGBurkhard Gess
Burkhard Gess
BBBordignon Benoit
Bordignon Benoit
AAAlexandre Altié
Alexandre Altié
YPYoung Peter
Young Peter
Michel  FontésMichel Fontés
Michel Fontés
We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients. We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors. The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors. Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.

25 January 2016 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SMSaleh Mones
Saleh Mones
BGBurkhard Gess
Burkhard Gess
BBBenoit Bordignon
Benoit Bordignon
AAAlexandre Altié
Alexandre Altié
PYPeter Young
Peter Young
Michel  FontésMichel Fontés
Michel Fontés